Skip to content

Change in AP at other companies

Eli Lilly logo
Eli LillyLLY
$2.55B+290%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$107.7M+150%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.93M+760%
uniQure logo
uniQureQURE
-$557K+73.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$68.71M-471%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$4.8M+44.1%

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s change in AP?
Denali Therapeutics Inc. (DNLI) reported change in AP of $3.88M in Q1 2026.
How has Denali Therapeutics Inc.'s change in AP changed year-over-year?
Denali Therapeutics Inc.'s change in AP increased by 246.8% year-over-year, from -$2.64M to $3.88M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.